SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.
Sperm Banks Lack Diverse Donors for Diverse Recipients
NEW ORLEANS — There aren’t enough sperm donors of diverse backgrounds for diverse recipients, and the racial breakdown of donors doesn’t match the U.S. male